Status:
COMPLETED
A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence
Lead Sponsor:
Graceway Pharmaceuticals, LLC
Conditions:
Basal Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The primary objective of this study is to assess whether basal cell carcinoma (BCC) lesions surgically treated with curettage, followed by imiquimod 5% cream as postsurgical adjuvant therapy, will hav...
Detailed Description
This was an open-label, phase IIIb, multicenter, single arm, historical-controlled study. Biopsy-confirmed BCC lesions (1 per subject) were excised by curettage, with no electrodessication. Approximat...
Eligibility Criteria
Inclusion
- Basal cell carcinoma
Exclusion
- Psoriasis
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT00129519
Start Date
January 1 2004
End Date
January 1 2006
Last Update
July 16 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Grass Valley, California, United States, 95945
2
Loma Linda, California, United States, 92354
3
New York, New York, United States, 10016